Lyfetec, Inc. Has Officially Received Its New Cusip Number

FT. LAUDERDALE, FL--(Marketwire - March 19, 2009) - LyfeTec, Inc. (PINKSHEETS: TSHL) has officially been notified that its new CUSIP shall be 55084L 10 6.

LyfeTec was notified today that it was assigned a new CUSIP number and expects to receive its new trading symbol shortly. This marks one of the key milestones in LyfeTec’s name change from Tri-Star Holdings. Now LyfeTec can proceed in full force with its new plans to capture a significant share of the global consumer health market under the LyfeTec Brand.

One of the first activities on the slate centers on the acquisition and integration of a profitable compounding pharmacy. Talks with the owner are nearing completion and the company expects to consummate the acquisition sometime in second quarter 2009. Revenues from this transaction are targeted to approximate $3,000,000 annually.

Phil Matteis states: “Steven and I are presently in the corporate office in Florida this week preparing the company’s new look for the products.”

Share Structure is: Authorized: 3,800,000,000 Total O/S: 2,603,371,186 Free Trading: 1,682,189,000 Restricted: 921,182,186 

UC Hub, Inc., Status Report:

UC HUB, a publicly traded OTCBB company, has issued 190,000,000 of its common restricted shares to LyfeTec for distribution on a non-discriminatory basis to all shareholders of Tri-Star Holdings who were on the share ledger prior to the name change and LyfeTec merger. These UC-HUB shares are intended to compensate shareholders for asset sale transaction related to business in the gold mining industry, part of the original Tri-Star Holdings business model. All shares shall be mailed according to sec laws by the transfer agent by Mar 30, 2009. Sorry for the delay.

Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.